AI IntelligenceJul 13, 2026Secondary Market
Article
ESALY
The FDA approved LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer's disease. The approval marks the first-of-its-kind anti-amyloid treatment worldwide, allowing at-home dosing.
Data Cube AI EditorialSource: PR Newswire
01
Source Brief
The FDA approved LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer's disease. The approval marks the first-of-its-kind anti-amyloid treatment worldwide, allowing at-home dosing.
02